Sanofi’s Post

View organization page for Sanofi, graphic

4,029,541 followers

The New England Journal of Medicine (NEJM Group) has published positive Phase 3 results regarding our medicine in children aged 1 to 11 years with eosinophilic esophagitis (#EoE). Read more about how we are working with Regeneron to change the standard of care for young children living with the disease. Read our press release: http://spkl.io/604447BBQ

  • No alternative text description for this image

This is a significant step forward in improving the lives of young children with eosinophilic esophagitis.��

Like
Reply
Darren Nelson 🚀 (We're hiring)

Innovative Leadership in Talent Solutions: Founder & CEO of Recruits Lab & BioJobs Lab, Driving Organizational Success through Cutting-Edge Recruitment Strategies.

1w

Fantastic news, Sanofi! 🎉 The positive Phase 3 results published by The New England Journal of Medicine regarding your medicine for children aged 1 to 11 with eosinophilic esophagitis (#EoE) are truly promising. It's exciting to see your collaboration with Regeneron potentially changing the standard of care for young patients facing this challenging condition. #Sanofi #Regeneron #EoE #MedicalResearch #Phase3Results #PediatricHealth

Like
Reply
Danny Rippy

Senior Pediatric Marketing Manager

5d

Ohh, that awesome! Well if you need an experienced pediatric representative who has great relationships with the pediatricians in the East Texas area, in pediatric pharmaceutical and healthcare services. I’m your guy.

So wonderful to see this ….

Like
Reply
USA and international Research .

Chief Executive Officer at USA and International Research Inc.

1w

Exciting news! Congratulations on the positive Phase 3 results for your medicine in children with eosinophilic esophagitis. Your collaboration with Regeneron is paving the way for better standards of care for young patients battling this disease.

Like
Reply
Martin Bonner

KI-gestützte Absatzmarktanalysen & Wachstumsstrategien | 𝖵𝖮𝖱𝖲𝖯𝖱𝖴𝖭𝖦𝗠𝗜𝗧𝗧𝗘𝗟𝗦𝗧𝗔𝗡𝗗 • 𝗕𝗢𝗡𝗡𝗘𝗥𝖢𝖮𝖭𝖲𝖴𝖫𝖳 • 𝗠𝗔𝗥𝗞𝗧𝖬𝖮𝖭𝖨𝖳𝖮𝖱™

1w

Great news from medical research! The positive Phase 3 results are a breakthrough for children with eosinophilic esophagitis. Our partnership with Regeneron will revolutionize the standard of care. A significant step forward for young patients.

Like
Reply
Dr. Magada Bashiri

I am a Certified Clinical Research Associate (CRA) & Medical Doctor with Research Ethics, Pharmaceutics, Clinical Trials, SOP, GCP & CTMS/EDC Experience

1w

Congratulations

Like
Reply
Isha Deshmukh

Digital Marketing Manager | SEO Specialist | Content Strategist | Email Marketing

5d

Fantastic news! 🌟 Excited to see positive impacts for young patients! #EoE

Like
Reply
Andy Anderson

US Marketing Head COPD Respiratory Specialty Care

1w

Inspiring!

See more comments

To view or add a comment, sign in

Explore topics